Published in Proc Natl Acad Sci U S A on May 11, 2009
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med (2010) 2.88
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc Natl Acad Sci U S A (2013) 1.55
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma (2012) 1.47
Application of synthetic photostable retinoids induces novel limb and facial phenotypes during chick embryogenesis in vivo. J Anat (2013) 1.38
Prevention of neural tube defects: a cross-sectional study of the uptake of folic acid supplementation in nearly half a million women. PLoS One (2014) 1.16
A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature (2009) 1.10
Environmental impact on vascular development predicted by high-throughput screening. Environ Health Perspect (2011) 1.05
In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. Chem Res Toxicol (2011) 1.00
Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures. Blood (2011) 1.00
In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice. Chem Res Toxicol (2012) 0.99
Castleman's disease--a two compartment model of HHV8 infection. Nat Rev Clin Oncol (2010) 0.95
A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case Rep Oncol (2010) 0.93
Phocomelia: a worldwide descriptive epidemiologic study in a large series of cases from the International Clearinghouse for Birth Defects Surveillance and Research, and overview of the literature. Am J Med Genet C Semin Med Genet (2011) 0.93
Vascular anomalies: from genetics toward models for therapeutic trials. Cold Spring Harb Perspect Med (2012) 0.91
Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today (2015) 0.90
Nitric oxide rescues thalidomide mediated teratogenicity. Sci Rep (2012) 0.88
Pericytes as targets in hereditary hemorrhagic telangiectasia. Front Genet (2015) 0.84
Thalidomide-a notorious sedative to a wonder anticancer drug. Curr Med Chem (2013) 0.83
The functional therapeutic chemical classification system. Bioinformatics (2013) 0.80
A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defects. Differentiation (2012) 0.80
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Mol Cancer Ther (2015) 0.79
Transient Inhibition of FGFR2b-ligands signaling leads to irreversible loss of cellular β-catenin organization and signaling in AER during mouse limb development. PLoS One (2013) 0.79
Inhibition of endothelial Slit2/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K/Akt pathway. Dig Dis Sci (2014) 0.78
Transcriptomic characterization of C57BL/6 mouse embryonic stem cell differentiation and its modulation by developmental toxicants. PLoS One (2014) 0.78
HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide. Sci Rep (2016) 0.78
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. Sci Rep (2016) 0.76
In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget (2016) 0.76
Thalidomide's early effects. Nat Med (2010) 0.75
Treatment of Hepatic Epithelioid Hemangioendothelioma: Finding Uses for Thalidomide in a New Era of Medicine. Case Rep Gastrointest Med (2015) 0.75
Tetra-phocomelia: the seal limb deformity - a case report. J Clin Diagn Res (2015) 0.75
Balance of the Sexes: Addressing Sex Differences in Preclinical Research. Yale J Biol Med (2016) 0.75
In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon. Springerplus (2016) 0.75
Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy. PLoS Med (2016) 0.75
New Findings in eNOS gene and Thalidomide Embryopathy Suggest pre-transcriptional effect variants as susceptibility factors. Sci Rep (2016) 0.75
High-throughput identification of small molecules that affect human embryonic vascular development. Proc Natl Acad Sci U S A (2017) 0.75
Thalidomide induces apoptosis in undifferentiated human induced pluripotent stem cells. In Vitro Cell Dev Biol Anim (2017) 0.75
VEGF-A and neuropilin 1 (NRP1) shape axon projections in the developing CNS via dual roles in neurons and blood vessels. Development (2017) 0.75
A series of normal stages in the development of the chick embryo. J Morphol (1951) 17.89
In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol (2002) 11.62
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
Thalidomide. Lancet (2004) 2.21
Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning. Nature (2008) 2.01
A developmental model for thalidomide defects. Nature (1998) 1.59
A short history of thalidomide embryopathy. Teratology (1988) 1.54
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol (1998) 1.46
Recognition of thalidomide defects. J Med Genet (1992) 1.40
Defects and disabilities of thalidomide children. Br Med J (1973) 1.37
Birth and death of cells in limb development: a mapping study. Dev Dyn (2006) 1.29
Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J (2007) 1.26
Thalidomide: a review of approved and investigational uses. Clin Ther (2003) 1.26
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res (2004) 1.25
New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol (2007) 1.24
The thin prep rat aortic ring assay: a modified method for the characterization of angiogenesis in whole mounts. Angiogenesis (2002) 1.16
Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. Chem Pharm Bull (Tokyo) (2006) 1.13
Early changes in limb buds of chick embryos after thalidomide treatment. J Embryol Exp Morphol (1966) 1.13
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res (2003) 1.07
Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol (2000) 1.06
Teratogenic effects of thalidomide and related substances. Lancet (1963) 1.05
Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol (2006) 1.05
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia (2005) 1.04
Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology (2000) 0.99
Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. Mol Pharm (2009) 0.97
Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab (2006) 0.95
A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal (2004) 0.95
Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem (2004) 0.93
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res (2006) 0.93
Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. Chem Pharm Bull (Tokyo) (2007) 0.88
Why study human limb malformations? J Anat (2003) 0.85
Smad7 misexpression during embryonic angiogenesis causes vascular dilation and malformations independently of vascular smooth muscle cell function. Dev Biol (2001) 0.83
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Pharmacy education: back to the basics? Pharmacotherapy (2003) 4.11
Ephrin-B2 and EphB1 mediate retinal axon divergence at the optic chiasm. Neuron (2003) 3.39
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Slit1 and Slit2 cooperate to prevent premature midline crossing of retinal axons in the mouse visual system. Neuron (2002) 2.77
DSCAM and DSCAML1 function in self-avoidance in multiple cell types in the developing mouse retina. Neuron (2009) 2.73
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Delta-Notch signalling controls commitment to a secretory fate in the zebrafish intestine. Development (2005) 2.53
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Thalidomide. Lancet (2004) 2.21
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
Altered Twist1 and Hand2 dimerization is associated with Saethre-Chotzen syndrome and limb abnormalities. Nat Genet (2005) 1.89
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res (2005) 1.84
Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol (2005) 1.81
Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol (2004) 1.73
Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res (2008) 1.73
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol (2002) 1.71
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol (2002) 1.68
Slit proteins regulate distinct aspects of retinal ganglion cell axon guidance within dorsal and ventral retina. J Neurosci (2006) 1.65
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Drug interactions in cancer therapy. Nat Rev Cancer (2006) 1.62
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res (2006) 1.60
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther (2009) 1.57
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc Natl Acad Sci U S A (2013) 1.55
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat (2003) 1.54
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol Ther (2002) 1.50
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol (2007) 1.46
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab (2010) 1.44
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem (2009) 1.44
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Ther (2007) 1.40
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res (2006) 1.40
2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy (2003) 1.40
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal (2008) 1.39
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34
Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res (2008) 1.34
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One (2011) 1.32
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol (2005) 1.29
Spatiotemporal features of early neuronogenesis differ in wild-type and albino mouse retina. J Neurosci (2002) 1.28
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol (2003) 1.26
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res (2004) 1.25
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.25
Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro (2005) 1.24
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (2006) 1.23
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res (2002) 1.23
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res (2011) 1.22
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res (2008) 1.22
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res (2012) 1.21
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol (2004) 1.21
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res (2006) 1.19
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics (2013) 1.19
Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One (2011) 1.19
Foxd1 is required for proper formation of the optic chiasm. Development (2004) 1.19
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics (2005) 1.18
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator. Cancer Biol Ther (2006) 1.17
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res (2009) 1.17